Company Quick10K Filing
Quick10K
Abbott
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$84.22 1,764 $148,579
10-Q 2019-06-30 Quarter: 2019-06-30
10-Q 2019-03-31 Quarter: 2019-03-31
10-K 2018-12-31 Annual: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-K 2017-12-31 Annual: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-Q 2017-06-30 Quarter: 2017-06-30
10-Q 2017-03-31 Quarter: 2017-03-31
10-K 2016-12-31 Annual: 2016-12-31
10-Q 2016-09-30 Quarter: 2016-09-30
10-Q 2016-06-30 Quarter: 2016-06-30
10-Q 2016-03-31 Quarter: 2016-03-31
10-K 2015-12-31 Annual: 2015-12-31
10-Q 2015-09-30 Quarter: 2015-09-30
10-Q 2015-06-30 Quarter: 2015-06-30
10-Q 2015-03-31 Quarter: 2015-03-31
10-K 2014-12-31 Annual: 2014-12-31
10-Q 2014-09-30 Quarter: 2014-09-30
10-Q 2014-06-30 Quarter: 2014-06-30
10-Q 2014-03-31 Quarter: 2014-03-31
10-K 2013-12-31 Annual: 2013-12-31
8-K 2019-10-11 Other Events
8-K 2019-09-09 Officers, Amend Bylaw, Exhibits
8-K 2019-07-17 Earnings, Exhibits
8-K 2019-06-20 Officers
8-K 2019-04-26
8-K 2019-04-17 Earnings, Exhibits
8-K 2019-02-24 Leave Agreement, Off-BS Arrangement, Other Events
8-K 2019-01-23 Earnings, Exhibits
8-K 2018-11-30 Enter Agreement, Leave Agreement, Off-BS Arrangement
8-K 2018-11-14 Officers
8-K 2018-10-28 Leave Agreement, Off-BS Arrangement, Other Events
8-K 2018-10-17 Earnings, Exhibits
8-K 2018-10-11 Officers
8-K 2018-09-27 Enter Agreement, Leave Agreement, Off-BS Arrangement, Off-BS Arrangement, Other Events, Exhibits
8-K 2018-09-18 Regulation FD
8-K 2018-07-18 Earnings, Exhibits
8-K 2018-06-22 Off-BS Arrangement, Other Events
8-K 2018-06-08 Officers, Amend Bylaw, Exhibits
8-K 2018-04-27
8-K 2018-04-18 Earnings, Exhibits
8-K 2018-03-22 Leave Agreement, Off-BS Arrangement, Other Events
8-K 2018-01-24 Earnings, Exhibits
ALLK Allakos 3,743
MRTX Mirati Therapeutics 3,085
ZYME Zymeworks 836
PRQR Proqr Therapeutics 316
LPCN Lipocine 59
SNSS Sunesis Pharmaceuticals 57
PLXP PLx Pharma 46
ACRS Aclaris 40
AEZS AEterna Zentaris 39
GNPX Genprex 14
ABT 2019-06-30
Note 1 - Basis of Presentation
Note 2 - New Accounting Standards
Note 3 - Revenue
Note 4 - Supplemental Financial Information
Note 5 - Changes in Accumulated Other Comprehensive Income (Loss)
Note 6 - Goodwill and Intangible Assets
Note 7 - Restructuring Plans
Note 8 - Incentive Stock Programs
Note 9 - Debt and Lines of Credit
Note 10 - Leases
Note 11 - Financial Instruments, Derivatives and Fair Value Measures
Note 12 - Litigation and Environmental Matters
Note 13 - Post-Employment Benefits
Note 14 - Taxes on Earnings
Note 15 - Segment Information
Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations
Part I. Financial Information
Item 4. Controls and Procedures
Part II. Other Information
Item 1. Legal Proceedings
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 6. Exhibits
EX-31.1 abt-20190630ex311883fcb.htm
EX-31.2 abt-20190630ex3125aa45d.htm
EX-32.1 abt-20190630ex3219f065f.htm
EX-32.2 abt-20190630ex32284c89d.htm

Abbott Earnings 2019-06-30

ABT 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

P12Mfalse--12-31Q220190000001800truetruetruetrueus-gaap:AccruedLiabilitiesabt:Post-EmploymentObligationsDeferredIncomeTaxesandOtherLong-termLiabilities850000000abt:DeferredIncomeTaxesandOtherAssetstrue0000001800us-gaap:TreasuryStockCommonMember2019-04-012019-06-300000001800us-gaap:CommonStockMember2019-04-012019-06-300000001800us-gaap:TreasuryStockCommonMember2019-01-012019-06-300000001800us-gaap:CommonStockMember2019-01-012019-06-300000001800us-gaap:TreasuryStockCommonMember2018-04-012018-06-300000001800us-gaap:CommonStockMember2018-04-012018-06-300000001800us-gaap:TreasuryStockCommonMember2018-01-012018-06-300000001800us-gaap:CommonStockMember2018-01-012018-06-300000001800us-gaap:RetainedEarningsMember2019-06-300000001800us-gaap:NoncontrollingInterestMember2019-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300000001800us-gaap:RetainedEarningsMember2019-03-310000001800us-gaap:NoncontrollingInterestMember2019-03-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-310000001800us-gaap:RetainedEarningsMember2018-12-310000001800us-gaap:NoncontrollingInterestMember2018-12-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000001800us-gaap:RetainedEarningsMember2018-06-300000001800us-gaap:NoncontrollingInterestMember2018-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-06-300000001800us-gaap:RetainedEarningsMember2018-03-310000001800us-gaap:NoncontrollingInterestMember2018-03-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-03-310000001800us-gaap:RetainedEarningsMember2017-12-310000001800us-gaap:NoncontrollingInterestMember2017-12-310000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2017-12-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2019-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2019-03-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-03-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-03-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-12-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-12-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2018-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2018-03-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-03-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-03-310000001800us-gaap:AccumulatedTranslationAdjustmentMember2017-12-310000001800us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2017-12-310000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2017-12-310000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2017-12-310000001800us-gaap:EmployeeStockOptionMember2019-01-012019-06-300000001800us-gaap:EmployeeStockOptionMember2019-06-300000001800us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-06-300000001800abt:RestrictedStockAwardsMember2019-01-012019-06-3000000018002021-07-012019-06-3000000018002019-07-012019-06-300000001800us-gaap:NonUsMemberabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:NutritionalProductsMemberabt:AdultNutritionalsMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:EstablishedPharmaceuticalProductsMemberabt:OtherMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:PointOfCareMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:MolecularMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:CoreLaboratoryMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:VascularProductsMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:StructuralHeartMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:RhythmManagementMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:NeuromodulationMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:HeartFailureMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:ElectrophysiologyMember2019-04-012019-06-300000001800country:USabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2019-04-012019-06-300000001800country:USabt:NutritionalProductsMemberabt:AdultNutritionalsMember2019-04-012019-06-300000001800country:USabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2019-04-012019-06-300000001800country:USabt:DiagnosticProductsMemberabt:PointOfCareMember2019-04-012019-06-300000001800country:USabt:DiagnosticProductsMemberabt:MolecularMember2019-04-012019-06-300000001800country:USabt:DiagnosticProductsMemberabt:CoreLaboratoryMember2019-04-012019-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:VascularProductsMember2019-04-012019-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:StructuralHeartMember2019-04-012019-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:RhythmManagementMember2019-04-012019-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:NeuromodulationMember2019-04-012019-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:HeartFailureMember2019-04-012019-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:ElectrophysiologyMember2019-04-012019-06-300000001800us-gaap:NonUsMemberus-gaap:AllOtherSegmentsMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:NutritionalProductsMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:EstablishedPharmaceuticalProductsMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMember2019-04-012019-06-300000001800country:USus-gaap:AllOtherSegmentsMember2019-04-012019-06-300000001800country:USabt:NutritionalProductsMember2019-04-012019-06-300000001800country:USabt:DiagnosticProductsMember2019-04-012019-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMember2019-04-012019-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMember2019-04-012019-06-300000001800abt:NutritionalProductsMemberabt:AdultNutritionalsMember2019-04-012019-06-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherMember2019-04-012019-06-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2019-04-012019-06-300000001800abt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2019-04-012019-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMember2019-04-012019-06-300000001800abt:DiagnosticProductsMemberabt:MolecularMember2019-04-012019-06-300000001800abt:DiagnosticProductsMemberabt:CoreLaboratoryMember2019-04-012019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:VascularProductsMember2019-04-012019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:StructuralHeartMember2019-04-012019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:RhythmManagementMember2019-04-012019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:NeuromodulationMember2019-04-012019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:HeartFailureMember2019-04-012019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:ElectrophysiologyMember2019-04-012019-06-300000001800us-gaap:NonUsMember2019-04-012019-06-300000001800us-gaap:AllOtherSegmentsMember2019-04-012019-06-300000001800country:US2019-04-012019-06-300000001800abt:NutritionalProductsMember2019-04-012019-06-300000001800abt:EstablishedPharmaceuticalProductsMember2019-04-012019-06-300000001800abt:DiagnosticProductsMember2019-04-012019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMember2019-04-012019-06-300000001800us-gaap:NonUsMemberabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:NutritionalProductsMemberabt:AdultNutritionalsMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:EstablishedPharmaceuticalProductsMemberabt:OtherMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:PointOfCareMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:MolecularMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:CoreLaboratoryMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:VascularProductsMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:StructuralHeartMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:RhythmManagementMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:NeuromodulationMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:HeartFailureMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:ElectrophysiologyMember2019-01-012019-06-300000001800country:USabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2019-01-012019-06-300000001800country:USabt:NutritionalProductsMemberabt:AdultNutritionalsMember2019-01-012019-06-300000001800country:USabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2019-01-012019-06-300000001800country:USabt:DiagnosticProductsMemberabt:PointOfCareMember2019-01-012019-06-300000001800country:USabt:DiagnosticProductsMemberabt:MolecularMember2019-01-012019-06-300000001800country:USabt:DiagnosticProductsMemberabt:CoreLaboratoryMember2019-01-012019-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:VascularProductsMember2019-01-012019-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:StructuralHeartMember2019-01-012019-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:RhythmManagementMember2019-01-012019-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:NeuromodulationMember2019-01-012019-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:HeartFailureMember2019-01-012019-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:ElectrophysiologyMember2019-01-012019-06-300000001800us-gaap:NonUsMemberus-gaap:AllOtherSegmentsMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:NutritionalProductsMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:EstablishedPharmaceuticalProductsMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMember2019-01-012019-06-300000001800country:USus-gaap:AllOtherSegmentsMember2019-01-012019-06-300000001800country:USabt:NutritionalProductsMember2019-01-012019-06-300000001800country:USabt:DiagnosticProductsMember2019-01-012019-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMember2019-01-012019-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMember2019-01-012019-06-300000001800abt:NutritionalProductsMemberabt:AdultNutritionalsMember2019-01-012019-06-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherMember2019-01-012019-06-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2019-01-012019-06-300000001800abt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2019-01-012019-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMember2019-01-012019-06-300000001800abt:DiagnosticProductsMemberabt:MolecularMember2019-01-012019-06-300000001800abt:DiagnosticProductsMemberabt:CoreLaboratoryMember2019-01-012019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:VascularProductsMember2019-01-012019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:StructuralHeartMember2019-01-012019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:RhythmManagementMember2019-01-012019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:NeuromodulationMember2019-01-012019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:HeartFailureMember2019-01-012019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:ElectrophysiologyMember2019-01-012019-06-300000001800us-gaap:NonUsMember2019-01-012019-06-300000001800us-gaap:AllOtherSegmentsMember2019-01-012019-06-300000001800country:US2019-01-012019-06-300000001800abt:NutritionalProductsMember2019-01-012019-06-300000001800abt:EstablishedPharmaceuticalProductsMember2019-01-012019-06-300000001800abt:DiagnosticProductsMember2019-01-012019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMember2019-01-012019-06-300000001800us-gaap:NonUsMemberabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:NutritionalProductsMemberabt:AdultNutritionalsMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:EstablishedPharmaceuticalProductsMemberabt:OtherMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:PointOfCareMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:MolecularMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:CoreLaboratoryMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:VascularProductsMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:StructuralHeartMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:RhythmManagementMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:NeuromodulationMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:HeartFailureMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:ElectrophysiologyMember2018-04-012018-06-300000001800country:USabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2018-04-012018-06-300000001800country:USabt:NutritionalProductsMemberabt:AdultNutritionalsMember2018-04-012018-06-300000001800country:USabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2018-04-012018-06-300000001800country:USabt:DiagnosticProductsMemberabt:PointOfCareMember2018-04-012018-06-300000001800country:USabt:DiagnosticProductsMemberabt:MolecularMember2018-04-012018-06-300000001800country:USabt:DiagnosticProductsMemberabt:CoreLaboratoryMember2018-04-012018-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:VascularProductsMember2018-04-012018-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:StructuralHeartMember2018-04-012018-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:RhythmManagementMember2018-04-012018-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:NeuromodulationMember2018-04-012018-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:HeartFailureMember2018-04-012018-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:ElectrophysiologyMember2018-04-012018-06-300000001800us-gaap:NonUsMemberus-gaap:AllOtherSegmentsMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:NutritionalProductsMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:EstablishedPharmaceuticalProductsMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMember2018-04-012018-06-300000001800country:USus-gaap:AllOtherSegmentsMember2018-04-012018-06-300000001800country:USabt:NutritionalProductsMember2018-04-012018-06-300000001800country:USabt:DiagnosticProductsMember2018-04-012018-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMember2018-04-012018-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMember2018-04-012018-06-300000001800abt:NutritionalProductsMemberabt:AdultNutritionalsMember2018-04-012018-06-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherMember2018-04-012018-06-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2018-04-012018-06-300000001800abt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2018-04-012018-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMember2018-04-012018-06-300000001800abt:DiagnosticProductsMemberabt:MolecularMember2018-04-012018-06-300000001800abt:DiagnosticProductsMemberabt:CoreLaboratoryMember2018-04-012018-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:VascularProductsMember2018-04-012018-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:StructuralHeartMember2018-04-012018-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:RhythmManagementMember2018-04-012018-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:NeuromodulationMember2018-04-012018-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:HeartFailureMember2018-04-012018-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:ElectrophysiologyMember2018-04-012018-06-300000001800us-gaap:NonUsMember2018-04-012018-06-300000001800us-gaap:AllOtherSegmentsMember2018-04-012018-06-300000001800country:US2018-04-012018-06-300000001800abt:NutritionalProductsMember2018-04-012018-06-300000001800abt:EstablishedPharmaceuticalProductsMember2018-04-012018-06-300000001800abt:DiagnosticProductsMember2018-04-012018-06-300000001800abt:CardiovascularAndNeuromodulationProductsMember2018-04-012018-06-300000001800us-gaap:NonUsMemberabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:NutritionalProductsMemberabt:AdultNutritionalsMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:EstablishedPharmaceuticalProductsMemberabt:OtherMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:PointOfCareMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:MolecularMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMemberabt:CoreLaboratoryMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:VascularProductsMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:StructuralHeartMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:RhythmManagementMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:NeuromodulationMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:HeartFailureMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMemberabt:ElectrophysiologyMember2018-01-012018-06-300000001800country:USabt:NutritionalProductsMemberabt:PediatricNutritionalsMember2018-01-012018-06-300000001800country:USabt:NutritionalProductsMemberabt:AdultNutritionalsMember2018-01-012018-06-300000001800country:USabt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2018-01-012018-06-300000001800country:USabt:DiagnosticProductsMemberabt:PointOfCareMember2018-01-012018-06-300000001800country:USabt:DiagnosticProductsMemberabt:MolecularMember2018-01-012018-06-300000001800country:USabt:DiagnosticProductsMemberabt:CoreLaboratoryMember2018-01-012018-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:VascularProductsMember2018-01-012018-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:StructuralHeartMember2018-01-012018-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:RhythmManagementMember2018-01-012018-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:NeuromodulationMember2018-01-012018-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:HeartFailureMember2018-01-012018-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMemberabt:ElectrophysiologyMember2018-01-012018-06-300000001800us-gaap:NonUsMemberus-gaap:AllOtherSegmentsMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:NutritionalProductsMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:EstablishedPharmaceuticalProductsMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:DiagnosticProductsMember2018-01-012018-06-300000001800us-gaap:NonUsMemberabt:CardiovascularAndNeuromodulationProductsMember2018-01-012018-06-300000001800country:USus-gaap:AllOtherSegmentsMember2018-01-012018-06-300000001800country:USabt:NutritionalProductsMember2018-01-012018-06-300000001800country:USabt:DiagnosticProductsMember2018-01-012018-06-300000001800country:USabt:CardiovascularAndNeuromodulationProductsMember2018-01-012018-06-300000001800abt:NutritionalProductsMemberabt:PediatricNutritionalsMember2018-01-012018-06-300000001800abt:NutritionalProductsMemberabt:AdultNutritionalsMember2018-01-012018-06-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:OtherMember2018-01-012018-06-300000001800abt:EstablishedPharmaceuticalProductsMemberabt:KeyEmergingMarketsMember2018-01-012018-06-300000001800abt:DiagnosticProductsMemberabt:RapidDiagnosticsMember2018-01-012018-06-300000001800abt:DiagnosticProductsMemberabt:PointOfCareMember2018-01-012018-06-300000001800abt:DiagnosticProductsMemberabt:MolecularMember2018-01-012018-06-300000001800abt:DiagnosticProductsMemberabt:CoreLaboratoryMember2018-01-012018-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:VascularProductsMember2018-01-012018-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:StructuralHeartMember2018-01-012018-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:RhythmManagementMember2018-01-012018-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:NeuromodulationMember2018-01-012018-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:HeartFailureMember2018-01-012018-06-300000001800abt:CardiovascularAndNeuromodulationProductsMemberabt:ElectrophysiologyMember2018-01-012018-06-300000001800us-gaap:NonUsMember2018-01-012018-06-300000001800us-gaap:AllOtherSegmentsMember2018-01-012018-06-300000001800country:US2018-01-012018-06-300000001800abt:NutritionalProductsMember2018-01-012018-06-300000001800abt:EstablishedPharmaceuticalProductsMember2018-01-012018-06-300000001800abt:DiagnosticProductsMember2018-01-012018-06-300000001800abt:CardiovascularAndNeuromodulationProductsMember2018-01-012018-06-300000001800abt:RestructuringPlanFrom2016To2018Member2019-06-300000001800abt:RestructuringPlan2017To2019StjudeAndAlereMember2019-06-300000001800abt:RestructuringPlanFrom2016To2018Member2018-12-310000001800abt:RestructuringPlan2017To2019StjudeAndAlereMember2018-12-310000001800us-gaap:SellingGeneralAndAdministrativeExpensesMemberabt:RestructuringPlan2017To2019StjudeAndAlereMember2019-01-012019-06-300000001800us-gaap:ResearchAndDevelopmentExpenseMemberabt:RestructuringPlan2017To2019StjudeAndAlereMember2019-01-012019-06-300000001800us-gaap:CostOfSalesMemberabt:RestructuringPlan2017To2019StjudeAndAlereMember2019-01-012019-06-300000001800abt:CepheaValveTechnologiesInc.Member2019-01-012019-03-3100000018002018-01-012018-12-310000001800abt:LongTermNotesDueIn2020At2.80PercentMember2019-02-242019-02-240000001800us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2019-04-012019-06-300000001800us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2019-01-012019-06-300000001800us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2018-04-012018-06-300000001800us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMember2018-01-012018-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-04-012018-06-300000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-012018-06-300000001800us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2019-04-012019-06-300000001800us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2019-01-012019-06-300000001800us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2018-04-012018-06-300000001800us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMember2018-01-012018-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2019-04-012019-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-04-012019-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-04-012019-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2018-04-012018-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-04-012018-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-04-012018-06-300000001800us-gaap:AccumulatedTranslationAdjustmentMember2018-01-012018-06-300000001800us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-01-012018-06-300000001800us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-01-012018-06-300000001800srt:RestatementAdjustmentMemberus-gaap:AccountingStandardsUpdate201602Member2019-01-010000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2019-04-012019-06-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2019-04-012019-06-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2019-04-012019-06-300000001800us-gaap:OperatingSegmentsMemberabt:CardiovascularAndNeuromodulationProductsMember2019-04-012019-06-300000001800us-gaap:OperatingSegmentsMember2019-04-012019-06-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2019-01-012019-06-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2019-01-012019-06-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2019-01-012019-06-300000001800us-gaap:OperatingSegmentsMemberabt:CardiovascularAndNeuromodulationProductsMember2019-01-012019-06-300000001800us-gaap:OperatingSegmentsMember2019-01-012019-06-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2018-04-012018-06-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2018-04-012018-06-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2018-04-012018-06-300000001800us-gaap:OperatingSegmentsMemberabt:CardiovascularAndNeuromodulationProductsMember2018-04-012018-06-300000001800us-gaap:OperatingSegmentsMember2018-04-012018-06-300000001800us-gaap:OperatingSegmentsMemberabt:NutritionalProductsMember2018-01-012018-06-300000001800us-gaap:OperatingSegmentsMemberabt:EstablishedPharmaceuticalProductsMember2018-01-012018-06-300000001800us-gaap:OperatingSegmentsMemberabt:DiagnosticProductsMember2018-01-012018-06-300000001800us-gaap:OperatingSegmentsMemberabt:CardiovascularAndNeuromodulationProductsMember2018-01-012018-06-300000001800us-gaap:OperatingSegmentsMember2018-01-012018-06-300000001800srt:MinimumMemberabt:LegalProceedingsAndEnvironmentalExposuresMember2019-06-300000001800srt:MaximumMemberabt:LegalProceedingsAndEnvironmentalExposuresMember2019-06-300000001800abt:LegalProceedingsAndEnvironmentalExposuresMember2019-06-300000001800us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:OtherAggregatedInvestmentsMember2019-06-300000001800us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:EquitySecuritiesMember2019-06-300000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:OtherAggregatedInvestmentsMember2019-06-300000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:EquitySecuritiesMember2019-06-300000001800us-gaap:OtherInvestmentsMember2019-06-300000001800us-gaap:EquitySecuritiesMember2019-06-300000001800us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:OtherAggregatedInvestmentsMember2018-12-310000001800us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:EquitySecuritiesMember2018-12-310000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:OtherAggregatedInvestmentsMember2018-12-310000001800us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:EquitySecuritiesMember2018-12-310000001800us-gaap:OtherInvestmentsMember2018-12-310000001800us-gaap:EquitySecuritiesMember2018-12-3100000018002019-01-012019-01-010000001800us-gaap:SegmentDiscontinuedOperationsMember2018-01-012018-06-300000001800abt:NutritionalProductsMember2019-06-300000001800abt:EstablishedPharmaceuticalProductsMember2019-06-300000001800abt:DiagnosticProductsMember2019-06-300000001800abt:CardiovascularAndNeuromodulationProductsMember2019-06-300000001800us-gaap:EstimateOfFairValueFairValueDisclosureMember2019-06-300000001800us-gaap:CarryingReportedAmountFairValueDisclosureMember2019-06-300000001800us-gaap:EstimateOfFairValueFairValueDisclosureMember2018-12-310000001800us-gaap:CarryingReportedAmountFairValueDisclosureMember2018-12-310000001800srt:WeightedAverageMember2019-01-012019-06-300000001800srt:MinimumMember2019-01-012019-06-300000001800us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2019-06-300000001800us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-06-300000001800abt:PostemploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-12-310000001800us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2018-12-310000001800us-gaap:AccruedLiabilitiesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-12-310000001800abt:DeferredIncomeTaxesAndOtherAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-06-300000001800abt:PrepaidExpensesAndOtherReceivablesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2019-06-300000001800abt:PrepaidExpensesAndOtherReceivablesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-06-300000001800abt:PrepaidExpensesAndOtherReceivablesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2018-12-310000001800abt:PrepaidExpensesAndOtherReceivablesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-12-310000001800us-gaap:PensionPlansDefinedBenefitMember2019-04-012019-06-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-04-012019-06-300000001800us-gaap:PensionPlansDefinedBenefitMember2019-01-012019-06-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-01-012019-06-300000001800us-gaap:PensionPlansDefinedBenefitMember2018-04-012018-06-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2018-04-012018-06-300000001800us-gaap:PensionPlansDefinedBenefitMember2018-01-012018-06-300000001800us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2018-01-012018-06-300000001800srt:MinimumMember2019-06-300000001800srt:MaximumMember2019-06-300000001800abt:LongTermNotesDueIn2020At2.80PercentMember2019-02-240000001800abt:LongTermNotesDueIn2020At2.80PercentMember2018-02-280000001800us-gaap:RetainedEarningsMember2018-01-010000001800us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-01-010000001800us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-01-010000001800us-gaap:TreasuryStockCommonMember2019-06-300000001800us-gaap:CommonStockMember2019-06-300000001800us-gaap:TreasuryStockCommonMember2019-03-310000001800us-gaap:CommonStockMember2019-03-310000001800us-gaap:TreasuryStockCommonMember2018-12-310000001800us-gaap:CommonStockMember2018-12-310000001800us-gaap:TreasuryStockCommonMember2018-06-300000001800us-gaap:CommonStockMember2018-06-300000001800us-gaap:TreasuryStockCommonMember2018-03-310000001800us-gaap:CommonStockMember2018-03-310000001800us-gaap:TreasuryStockCommonMember2017-12-310000001800us-gaap:CommonStockMember2017-12-310000001800abt:StJudeMedicalInc.Memberus-gaap:EquitySecuritiesMember2019-06-3000000018002018-06-3000000018002017-12-310000001800abt:CepheaValveTechnologiesInc.Member2019-03-310000001800us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-06-300000001800us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-310000001800us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2019-06-300000001800us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2019-06-300000001800us-gaap:FairValueMeasurementsRecurringMember2019-06-300000001800us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-310000001800us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-310000001800us-gaap:FairValueMeasurementsRecurringMember2018-12-310000001800us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-06-300000001800us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-06-300000001800us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2019-06-300000001800us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-12-310000001800us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2018-12-310000001800us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2018-12-310000001800exch:XNYS2019-01-012019-06-300000001800exch:XCHI2019-01-012019-06-3000000018002021-07-012019-01-012019-06-3000000018002019-07-012019-01-012019-06-300000001800abt:RestructuringPlanFrom2016To2018Member2019-01-012019-06-300000001800abt:RestructuringPlan2017To2019StjudeAndAlereMember2019-01-012019-06-3000000018002018-12-310000001800us-gaap:NoncontrollingInterestMember2019-04-012019-06-300000001800us-gaap:NoncontrollingInterestMember2019-01-012019-06-300000001800us-gaap:NoncontrollingInterestMember2018-04-012018-06-300000001800us-gaap:NoncontrollingInterestMember2018-01-012018-06-300000001800us-gaap:ForeignExchangeForwardMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-01-012019-06-300000001800srt:MaximumMember2019-04-012019-06-300000001800srt:MaximumMember2019-01-012019-06-300000001800us-gaap:RetainedEarningsMember2019-04-012019-06-300000001800us-gaap:RetainedEarningsMember2019-01-012019-06-300000001800us-gaap:RetainedEarningsMember2018-04-012018-06-300000001800us-gaap:RetainedEarningsMember2018-01-012018-06-300000001800us-gaap:CorporateNonSegmentMember2019-04-012019-06-300000001800us-gaap:CorporateNonSegmentMember2019-01-012019-06-300000001800us-gaap:CorporateNonSegmentMember2018-04-012018-06-300000001800us-gaap:CorporateNonSegmentMember2018-01-012018-06-3000000018002018-02-2800000018002019-06-300000001800us-gaap:MaterialReconcilingItemsMember2019-04-012019-06-3000000018002019-04-012019-06-300000001800us-gaap:MaterialReconcilingItemsMember2019-01-012019-06-3000000018002019-01-012019-06-300000001800us-gaap:MaterialReconcilingItemsMember2018-04-012018-06-3000000018002018-04-012018-06-300000001800us-gaap:MaterialReconcilingItemsMember2018-01-012018-06-3000000018002018-01-012018-06-30iso4217:USDxbrli:purexbrli:sharesiso4217:USDxbrli:sharesabt:segment

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

         QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

OR

          TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                   to                  

Commission File No. 1-2189

ABBOTT LABORATORIES

An Illinois Corporation

    

I.R.S. Employer Identification No.

36-0698440

100 Abbott Park Road

Abbott ParkIllinois 60064-6400

Telephone:  (224) 667-6100

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class

    

Trading Symbol(s)

    

Name of Each Exchange on Which Registered

Common Shares, Without Par Value

ABT

New York Stock Exchange
Chicago Stock Exchange, Inc.

Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

    

Accelerated Filer

Non-Accelerated Filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of June 30, 2019, Abbott Laboratories had 1,767,397,615 common shares without par value outstanding.

Table of Contents

Abbott Laboratories

Table of Contents

Page

Part I - Financial Information

Item 1. Financial Statements and Supplementary Data

Condensed Consolidated Statement of Earnings

3

Condensed Consolidated Statement of Comprehensive Income

4

Condensed Consolidated Balance Sheet

5

Condensed Consolidated Statement of Shareholders’ Investment

6

Condensed Consolidated Statement of Cash Flows

8

Notes to the Condensed Consolidated Financial Statements

9

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

21

Item 4. Controls and Procedures

26

Part II - Other Information

Item 1. Legal Proceedings

26

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

27

Item 6. Exhibits

28

Signature

29

2

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited)

(dollars in millions except per share data; shares in thousands)

Three Months Ended June 30

Six Months Ended June 30

    

2019

    

2018

    

2019

    

2018

Net sales

$

7,979

$

7,767

$

15,514

$

15,157

Cost of products sold, excluding amortization of intangible assets

 

3,279

 

3,282

 

6,439

 

6,349

Amortization of intangible assets

 

483

 

562

 

969

 

1,146

Research and development

 

577

 

575

 

1,249

 

1,164

Selling, general and administrative

 

2,434

 

2,466

 

4,912

 

5,008

Total operating cost and expenses

 

6,773

 

6,885

 

13,569

 

13,667

Operating earnings

 

1,206

 

882

 

1,945

 

1,490

Interest expense

 

168

 

210

 

339

 

437

Interest (income)

 

(22)

 

(21)

 

(45)

 

(49)

Net foreign exchange (gain) loss

 

(4)

 

(6)

 

2

 

(9)

Net loss on extinguishment of debt

14

Other (income) expense, net

 

(38)

 

(78)

 

(85)

 

(111)

Earnings from continuing operations before taxes

 

1,102

 

777

 

1,734

 

1,208

Taxes on earnings from continuing operations

 

96

 

59

 

56

 

81

Earnings from continuing operations

 

1,006

 

718

 

1,678

 

1,127

Earnings from discontinued operations, net of tax

15

24

Net Earnings

 

$

1,006

 

$

733

$

1,678

 

$

1,151

Basic Earnings Per Common Share —

Continuing operations

 

$

0.57

 

$

0.41

$

0.94

 

$

0.64

Discontinued operations

 

 

0.01

 

 

0.01

Net earnings

 

$

0.57

 

$

0.42

$

0.94

 

$

0.65

Diluted Earnings Per Common Share —

Continuing operations

 

$

0.56

 

$

0.40

$

0.94

 

$

0.63

Discontinued operations

 

 

0.01

 

 

0.01

Net earnings

 

$

0.56

 

$

0.41

$

0.94

 

$

0.64

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share

 

1,768,904

 

1,757,836

 

1,766,182

 

1,755,691

Dilutive Common Stock Options

 

12,513

 

11,114

 

12,904

 

11,490

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options

 

1,781,417

 

1,768,950

 

1,779,086

 

1,767,181

Outstanding Common Stock Options Having No Dilutive Effect

 

247

 

93

 

247

 

93

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

3

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Comprehensive Income

(Unaudited)

(dollars in millions)

Three Months Ended June 30

Six Months Ended June 30

    

2019

    

2018

    

2019

    

2018

Net Earnings

$

1,006

$

733

$

1,678

$

1,151

Foreign currency translation gain (loss) adjustments

 

91

 

(1,359)

 

213

 

(1,026)

Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $7 and $14 in 2019 and $15 and $32 in 2018

 

26

 

61

 

49

 

84

Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $(7) and $(15) in 2019 and $48 and $28 in 2018

 

(12)

 

118

 

(41)

 

86

Other comprehensive income (loss)

 

105

 

(1,180)

 

221

 

(856)

Comprehensive Income (Loss)

 

$

1,111

 

$

(447)

$

1,899

 

$

295

June 30, 

December 31, 

    

2019

    

2018

Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:

Cumulative foreign currency translation (loss) adjustments

$

(4,699)

$

(4,912)

Net actuarial (losses) and prior service (costs) and credits

 

(2,677)

 

(2,726)

Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other

 

11

 

52

Accumulated other comprehensive income (loss)

$

(7,365)

$

(7,586)

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

4

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Balance Sheet

(Unaudited)

(dollars in millions)

June 30, 

December 31, 

    

2019

    

2018

Assets

Current Assets:

Cash and cash equivalents

$

3,137

$

3,844

Short-term investments

 

239

 

242

Trade receivables, less allowances of $338 in 2019 and $314 in 2018

 

5,548

 

5,182

Inventories:

Finished products

 

2,786

 

2,407

Work in process

 

584

 

499

Materials

 

982

 

890

Total inventories

 

4,352

 

3,796

Prepaid expenses and other receivables

 

1,919

 

1,568

Total Current Assets

 

15,195

 

14,632

Investments

 

851

 

897

Property and equipment, at cost

 

16,331

 

15,706

Less: accumulated depreciation and amortization

 

8,506

 

8,143

Net property and equipment

 

7,825

 

7,563

Intangible assets, net of amortization

 

18,091

 

18,942

Goodwill

 

23,329

 

23,254

Deferred income taxes and other assets

 

3,136

 

1,885

 

$

68,427

 

$

67,173

Liabilities and Shareholders’ Investment

Current Liabilities:

Short-term borrowings

 

$

204

$

200

Trade accounts payable

 

3,222

 

2,975

Salaries, wages and commissions

 

1,018

 

1,182

Other accrued liabilities

 

3,961

 

3,780

Dividends payable

 

566

 

563

Income taxes payable

 

83

 

305

Current portion of long-term debt

 

8

 

7

Total Current Liabilities

 

9,062

 

9,012

Long-term debt

 

18,982

 

19,359

Post-employment obligations, deferred income taxes and other long-term liabilities

 

8,489

 

8,080

Commitments and Contingencies

Shareholders’ Investment:

Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued

 

 

Common shares, without par value Authorized — 2,400,000,000 shares
Issued at stated capital amount - Shares: 2019: 1,976,248,129 ; 2018: 1,971,189,465

 

23,665

 

23,512

Common shares held in treasury, at cost — Shares: 2019: 208,850,514 ; 2018: 215,570,043

 

(9,659)

 

(9,962)

Earnings employed in the business

 

25,045

 

24,560

Accumulated other comprehensive income (loss)

 

(7,365)

 

(7,586)

Total Abbott Shareholders’ Investment

 

31,686

 

30,524

Noncontrolling Interests in Subsidiaries

 

208

 

198

Total Shareholders’ Investment

 

31,894

 

30,722

 

$

68,427

$

67,173

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

5

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Shareholders’ Investment

(Unaudited)

(in millions except shares and per share data)

Three Months Ended June 30

    

2019

    

2018

Common Shares:

 

  

 

  

Balance at March 31

 

  

 

  

Shares: 2019: 1,973,472,506 ; 2018: 1,969,331,007

$

23,461

$

23,223

Issued under incentive stock programs

 

  

 

Shares: 2019: 2,775,623 ; 2018: 244,359

 

111

 

10

Share-based compensation

 

106

 

90

Issuance of restricted stock awards

 

(13)

 

(6)

Balance at June 30

Shares: 2019: 1,976,248,129 ; 2018: 1,969,575,366

$

23,665

$

23,317

Common Shares Held in Treasury:

 

  

 

  

Balance at March 31 Shares: 2019: 209,291,244 ; 2018: 216,143,241

$

(9,679)

$

(9,947)

Issued under incentive stock programs

Shares: 2019: 441,459 ; 2018: 891,641

 

21

 

41

Purchased

Shares: 2019: 729 ; 2018: 4,482

 

(1)

 

(1)

Balance at June 30

Shares: 2019: 208,850,514 ; 2018: 215,256,082

$

(9,659)

$

(9,907)

Earnings Employed in the Business:

 

  

 

  

Balance at March 31

$

24,613

$

23,856

Net earnings

 

1,006

 

733

Cash dividends declared on common shares (per share — 2019: $0.32 ; 2018: $0.28)

 

(568)

 

(495)

Effect of common and treasury share transactions

 

(6)

 

(14)

Balance at June 30

$

25,045

$

24,080

Accumulated Other Comprehensive Income (Loss):

 

  

 

  

Balance at March 31

$

(7,470)

$

(5,733)

Other comprehensive income (loss)

 

105

 

(1,180)

Balance at June 30

$

(7,365)

$

(6,913)

Noncontrolling Interests in Subsidiaries:

 

  

 

  

Balance at March 31

$

204

$

202

Noncontrolling Interests’ share of income, business combinations, net of distributions
and share repurchases

 

4

 

(5)

Balance at June 30

$

208

$

197

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

6

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Shareholders’ Investment

(Unaudited)

(in millions except shares and per share data)

Six Months Ended June 30

    

2019

    

2018

Common Shares:

Balance at January 1

Shares: 2019: 1,971,189,465 ; 2018: 1,965,908,188

$

23,512

$

23,206

Issued under incentive stock programs

Shares: 2019: 5,058,664 ; 2018: 3,667,178

 

187

 

112

Share-based compensation

 

343

 

315

Issuance of restricted stock awards

 

(377)

 

(316)

Balance at June 30

Shares: 2019: 1,976,248,129 ; 2018: 1,969,575,366

$

23,665

$

23,317

Common Shares Held in Treasury:

Balance at January 1

Shares: 2019: 215,570,043 ; 2018: 222,305,719

$

(9,962)

$

(10,225)

Issued under incentive stock programs

Shares: 2019: 6,986,386 ; 2018: 7,294,336

324

 

333

Purchased

 

Shares: 2019: 266,857 ; 2018: 244,699

 

(21)

 

(15)

Balance at June 30

Shares: 2019: 208,850,514 ; 2018: 215,256,082

$

(9,659)

$

(9,907)

Earnings Employed in the Business:

Balance at January 1

$

24,560

$

23,978

Impact of adoption of new accounting standards

 

 

15

Net earnings

 

1,678

 

1,151

Cash dividends declared on common shares (per share — 2019: $0.64 ; 2018: $0.56)

 

(1,136)

 

(988)

Effect of common and treasury share transactions

 

(57)

 

(76)

Balance at June 30

$

25,045

$

24,080

Accumulated Other Comprehensive Income (Loss):

Balance at January 1

$

(7,586)

$

(6,062)

Impact of adoption of new accounting standard

 

 

5

Other comprehensive income (loss)

 

221

 

(856)

Balance at June 30

$

(7,365)

$

(6,913)

Noncontrolling Interests in Subsidiaries:

Balance at January 1

$

198

$

201

Noncontrolling Interests’ share of income, business combinations, net of distributions
and share repurchases

 

10

 

(4)

Balance at June 30

$

208

$

197

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

7

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Cash Flows

(Unaudited)

(dollars in millions)

Six Months Ended June 30

    

2019

    

2018

Cash Flow From (Used in) Operating Activities:

Net earnings

$

1,678

$

1,151

Adjustments to reconcile net earnings to net cash from operating activities -

Depreciation

 

535

 

556

Amortization of intangible assets

 

969

 

1,146

Share-based compensation

340

313

Amortization of inventory step-up

32

Trade receivables

 

(335)

 

(137)

Inventories

 

(540)

 

(336)

Other, net

 

(875)

 

(373)

Net Cash From Operating Activities

 

1,772

 

2,352

Cash Flow From (Used in) Investing Activities:

Acquisitions of property and equipment

 

(803)

 

(573)

Acquisitions of businesses and technologies, net of cash acquired

(160)

(43)

Proceeds from business dispositions

48

48

Sales (purchases) of other investment securities, net

 

2

 

(42)

Other

 

19

 

73

Net Cash (Used in) Investing Activities

 

(894)

 

(537)

Cash Flow From (Used in) Financing Activities:

Net borrowings (repayments) of short-term debt and other

 

40

 

140

Repayments of long-term debt

 

(521)

 

(7,280)

Purchases of common shares

 

(221)

 

(131)

Proceeds from stock options exercised

 

244

 

170

Dividends paid

 

(1,133)

 

(985)

Net Cash (Used in) Financing Activities

 

(1,591)

 

(8,086)

Effect of exchange rate changes on cash and cash equivalents

 

6

 

(71)

Net Decrease in Cash and Cash Equivalents

 

(707)

 

(6,342)

Cash and Cash Equivalents, Beginning of Year

 

3,844

 

9,407

Cash and Cash Equivalents, End of Period

 

$

3,137

 

$

3,065

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

8

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

June 30, 2019

(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements.  However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made.  It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2018.  The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

Note 2 — New Accounting Standards

Recently Adopted Accounting Standards

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-02, Leases, which requires lessees to measure and recognize a lease asset and liability on the balance sheet for most leases, including operating leases.  Abbott adopted the new standard as of January 1, 2019 using the modified retrospective approach and applied the standard’s transition provisions as of January 1, 2019.  As a result, no changes were made to the December 31, 2018 Consolidated Balance Sheet. Abbott elected to apply the package of practical expedients related to transition. These practical expedients allowed Abbott to carry forward its historical assessments of whether any existing contracts are or contain leases, the lease classification for each lease existing at January 1, 2019, and whether any initial direct costs for such leases qualified for capitalization.

The new lease accounting standard does not have a material impact on the amounts reported in the Condensed Consolidated Statement of Earnings but does have a material impact on the amounts reported in the Condensed Consolidated Balance Sheet.  Adoption of the new standard resulted in the recording of approximately $850 million of new right of use (ROU) assets and additional liabilities for operating leases on the Condensed Consolidated Balance Sheet as of January 1, 2019.

Recent Accounting Standards Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset.  The new standard will be effective for Abbott at the beginning of 2020, with early adoption permitted. Abbott is currently assessing the impact of this new standard on its consolidated financial statements.

Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements.  Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Cardiovascular and Neuromodulation Products.  Diabetes Care is a non-reportable segment and is included in Other.

9

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

June 30, 2019

(Unaudited)

The following tables provide detail by sales category:

Three Months Ended June 30, 2019

Three Months Ended June 30, 2018

(in millions)

    

U.S.

    

Int’l

    

Total

    

U.S.

    

Int’l

    

Total

Established Pharmaceutical Products —

 

  

 

  

 

  

 

  

 

  

 

  

Key Emerging Markets

$

$

853

$

853

$

$

866

$

866

Other

 

 

255

 

255

 

 

263

263

Total

 

 

1,108

 

1,108

 

 

1,129

 

1,129

Nutritionals —

 

  

 

  

 

  

 

  

 

  

 

  

Pediatric Nutritionals

 

475

 

576

 

1,051

 

469

 

582

 

1,051

Adult Nutritionals

 

311

 

513

 

824

 

312